Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study

In the originally published article, there was a mixture of Endpoint (LS mean) and Endpoint (mean). The correct mean is described as shown below.

In the sentences beginning “The change in VAS score…” and “Additionally, a significant decrease in the VAS score…” under heading “Efficacy” in Results section, the term “LS mean” should have read “mean”. The complete sentences should read as follows:

The change in VAS score from baseline to Week 12 was significantly higher in the mirogabalin and NSAIDs group versus the NSAIDs group [difference in mean (95% CI), − 9.9 (− 18.4, − 1.4), P = 0.0229; by t test] (Fig. 3b). Similar significant results were obtained in LOCF and BOCF. Additionally, a significant decrease in the VAS score was shown in the mirogabalin and NSAIDs group compared with the NSAIDs group starting at Week 8 [difference in mean (95% CI), − 13.7 (− 21.7, − 5.7), P = 0.0009; by t test] (Fig. 3b).

The corrected Fig. 3 and Table 4 of this article should have appeared as shown below.

In the sentence beginning “In the NSAIDs group…” under heading “Safety” in Results section, the text “the outcome was” should have read “the outcomes were”. The complete sentence should read as follows:

In the NSAIDs group, there was one serious TEAE of breast cancer, which was determined to have no causal relationship to NSAID use; the outcomes were mild, and no deaths were reported during the study period.

The corrected Supplementary file is uploaded with this Correction article.

The original article has been corrected.

Fig. 3figure 3

a VAS score for leg pain and b its change from baseline (mITT population). Data are mean ± SD. No statistical tests were conducted for the results shown in a; analysis by t test was conducted to obtain the P values in b. *P < 0.05 for between-group differences. **P < 0.01 for between-group differences. BOCF baseline observation carried forward, CI confidence interval, LOCF last observation carried forward, mITT modified intention-to-treat, NSAIDs non-steroidal anti-inflammatory drugs, SD standard deviation, VAS visual analog scale

Table 4 PGIC at Week 12 in patients completing the study (mITT population)

留言 (0)

沒有登入
gif